Your Thyroid Is Attacking Itself. Here's Why Your Genes May Be the Answer.

HLA genes sit on the surface of antigen-presenting cells. Their job is to capture fragments of foreign proteins (from viruses, bacteria, food) and display them to T-cells. T-cells then decide: attack or ignore. If the displayed fragment looks like “self,” the T-cell should ignore it. If it looks like a threat, the T-cell activates.

HLA-DQ2, carried by roughly 25-30% of people with European ancestry, has a specific binding pocket. That pocket happens to recognize thyroid peroxidase (TPO) and thyroglobulin (the proteins your thyroid makes) as structurally similar to viral proteins. If you carry HLA-DQ2, your immune system is primed to see your own thyroid as a foreign invader. This is why HLA-DQ2 shows up in roughly 90% of Graves’ disease patients. You don’t develop the disease just from carrying the gene, but without it, Graves’ disease is extremely rare.

What this means in your body: your immune system has a biological “wanted poster” for thyroid proteins. When you encounter a viral infection (like EBV or a respiratory virus), or when stress spikes your cortisol, or when you’re selenium deficient, the stage is set. A T-cell stumbles across a thyroid protein fragment and says, “I’ve seen this before,” and activates. That activation cascades.

Imagine T-cells as soldiers. CTLA4 is the sergeant who pulls them back when the battle is over. After T-cells activate and attack a pathogen, CTLA4 sends a signal: enough. Stand down. This is called “immune tolerance,” and it prevents your immune system from destroying its own tissue after fighting an infection.

The CTLA4 +49A>G variant, carried by roughly 45% of the population, reduces CTLA4 expression. That means the emergency brake on T-cell activation is weaker. T-cells stay active longer and fire more readily. In the context of Graves’ disease, this means the immune attack on your thyroid doesn’t turn off the way it should. A normal person might have a brief T-cell response to thyroid antigen, then CTLA4 kicks in and restores tolerance. In you, that tolerance checkpoint fails.

What this means in your body: your immune system is like a car with a soft brake pedal. It accelerates fine (you can fight infections normally), but once acceleration starts, stopping takes longer. In the context of thyroid autoimmunity, this means flare-ups last longer and are triggered more easily by minor immune challenges.

TNF-alpha is a cytokine. Think of it as a megaphone. When your immune system detects a threat, TNF-alpha shouts the signal to every cell in the vicinity: activate, attack, multiply. TNF-alpha is essential for fighting infections. But it’s also a key driver of autoimmune disease.

The TNF -308G>A variant, carried by roughly 30% of people with European ancestry, increases TNF-alpha production. Your immune system is essentially yelling louder during activation; inflammatory signals spread more widely and persist longer. In Graves’ disease, high TNF-alpha amplifies the Th1 response against thyroid antigen. It also increases intestinal permeability (leaky gut), which allows thyroid-mimicking proteins from bacteria to cross into the bloodstream, further amplifying the cross-reactive immune response.

What this means in your body: when you get a minor infection, or experience stress, or eat a food that triggers low-level immune activation, your inflammatory response overshoots. Your thyroid comes under fire. The attack is more intense and lasts longer than it should. Over time, repeated activation episodes lead to persistent TSI antibody production.

IL-6 is another inflammatory cytokine. While TNF-alpha is the initial shout, IL-6 keeps the inflammation going. It recruits immune cells, promotes Th17 and Th1 differentiation (both pro-autoimmune), and is particularly potent in driving thyroid-specific autoimmunity.

The IL6 -174G>C variant, carried by roughly 40% of the population, increases IL-6 production. Your baseline inflammatory tone is higher, and during immune activation, IL-6 signals are amplified, which drives both the initial thyroid attack and chronic immune activation. Studies show that people with Graves’ disease have elevated IL-6 at baseline and even higher levels during flares. If you carry the C allele, your immune system is pre-wired to produce more IL-6 in response to triggers.

What this means in your body: inflammation is like a fire. TNF is the spark. IL-6 is the kindling that keeps it burning. Even after the initial trigger passes, IL-6 keeps the thyroid-specific T-cell response alive. This is why Graves’ disease flares can persist for weeks after the original trigger (an infection, stress) is gone.

PTPN22 is a protein tyrosine phosphatase. It’s an enzyme that helps T-cells make the critical decision: “Is this self or non-self?” It sits at the crossroads where T-cells evaluate antigen and decide whether to activate. When PTPN22 works correctly, it enforces tolerance to self-antigens and appropriate rejection of foreign antigens.

The PTPN22 C1858T variant (1858T allele), carried by roughly 5-10% of people with European ancestry, impairs this tolerance checkpoint. T-cells become more easily activated against self-antigens, including thyroid proteins. This variant is specifically enriched in Graves’ disease, type 1 diabetes, celiac disease, and lupus. It’s one of the clearest genetic risk factors for crossing the line from “tolerant” to “autoimmune.”

What this means in your body: your T-cell decision-making apparatus is defective. A viral infection that would trigger a brief, self-limited response in someone without the variant can trigger a persistent autoimmune response in you. Regulatory T-cells (Tregs), which normally suppress autoreactive T-cells, are less effective. The brake is not just soft, like in CTLA4; it’s partially broken.

IRF5 is a transcription factor that controls interferon-beta (IFN-beta) production. Interferon-beta is how your cells signal that a virus is present. It’s essential for fighting viral infections. But it’s also a powerful activator of Th1 cells, which are the T-cell subset that attacks tissue in Graves’ disease.

The IRF5 variant (CGGGG insertion), carried by roughly 15-20% of the population and enriched in autoimmune disease, increases interferon-beta production and prolongs the antiviral response. Your immune system stays in “viral defense mode” longer after an infection clears, and Th1 cells remain activated. In Graves’ disease, this means an EBV reactivation, a respiratory virus, or even a minor infection can trigger a thyroid-specific Th1 response that persists for weeks or months.

What this means in your body: your antiviral response doesn’t have an “off switch.” A normal person gets a cold, fights it, recovers, and the immune response resets. You get a cold, fight it, and the interferon signal keeps firing, keeping Th1 cells active and the thyroid under immune attack long after the virus is cleared.